Fed Circ decides fate of Orange Book patent covering blockbuster J&J schizophrenia drug

Court hears arguments from J&J and Teva to determine whether a patent blocking generic versions of Invega Sustenna will be upheld | J&J fights to protect its last remaining Orange Book patent covering Invega Sustenna.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Teva wins Fed Circ appeal over J&J’s schizophrenia drug

2 April 2024 Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.

Americas

Janssen seeks to halt generic schizophrenia drug

22 February 2022 Johnson & Johnson unit Janssen Pharmaceuticals has filed a suit against Intas Pharmaceuticals, seeking to block the India-based drugmaker from launching a generic version of schizophrenia drug Invega Sustenna (paliperidone palmitate).

Americas

Janssen sues Mylan to block generic of schizophrenia drug

29 September 2020 A Johnson & Johnson company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.